[1]
Zucca E, Bertoni F, Stathis A, Cavalli F. Marginal zone lymphomas. Hematology/oncology clinics of North America. 2008 Oct:22(5):883-901, viii. doi: 10.1016/j.hoc.2008.07.011. Epub
[PubMed PMID: 18954742]
[2]
Khalil MO, Morton LM, Devesa SS, Check DP, Curtis RE, Weisenburger DD, Dores GM. Incidence of marginal zone lymphoma in the United States, 2001-2009 with a focus on primary anatomic site. British journal of haematology. 2014 Apr:165(1):67-77. doi: 10.1111/bjh.12730. Epub 2014 Jan 12
[PubMed PMID: 24417667]
[3]
Sagaert X, De Wolf-Peeters C, Noels H, Baens M. The pathogenesis of MALT lymphomas: where do we stand? Leukemia. 2007 Mar:21(3):389-96
[PubMed PMID: 17230229]
[4]
Ruland J, Duncan GS, Elia A, del Barco Barrantes I, Nguyen L, Plyte S, Millar DG, Bouchard D, Wakeham A, Ohashi PS, Mak TW. Bcl10 is a positive regulator of antigen receptor-induced activation of NF-kappaB and neural tube closure. Cell. 2001 Jan 12:104(1):33-42
[PubMed PMID: 11163238]
[5]
Ruland J, Duncan GS, Wakeham A, Mak TW. Differential requirement for Malt1 in T and B cell antigen receptor signaling. Immunity. 2003 Nov:19(5):749-58
[PubMed PMID: 14614861]
[6]
Troppan K, Wenzl K, Neumeister P, Deutsch A. Molecular Pathogenesis of MALT Lymphoma. Gastroenterology research and practice. 2015:2015():102656. doi: 10.1155/2015/102656. Epub 2015 Apr 1
[PubMed PMID: 25922601]
[7]
Teckie S, Qi S, Chelius M, Lovie S, Hsu M, Noy A, Portlock C, Yahalom J. Long-term outcome of 487 patients with early-stage extra-nodal marginal zone lymphoma. Annals of oncology : official journal of the European Society for Medical Oncology. 2017 May 1:28(5):1064-1069. doi: 10.1093/annonc/mdx025. Epub
[PubMed PMID: 28327924]
Level 2 (mid-level) evidence
[8]
Perry C, Herishanu Y, Metzer U, Bairey O, Ruchlemer R, Trejo L, Naparstek E, Sapir EE, Polliack A. Diagnostic accuracy of PET/CT in patients with extranodal marginal zone MALT lymphoma. European journal of haematology. 2007 Sep:79(3):205-9
[PubMed PMID: 17662066]
[9]
Suekane H, Iida M, Kuwano Y, Kohrogi N, Yao T, Iwashita A, Fujishima M. Diagnosis of primary early gastric lymphoma. Usefulness of endoscopic mucosal resection for histologic evaluation. Cancer. 1993 Feb 15:71(4):1207-13
[PubMed PMID: 8435794]
[10]
Thieblemont C, Cascione L, Conconi A, Kiesewetter B, Raderer M, Gaidano G, Martelli M, Laszlo D, Coiffier B, Lopez Guillermo A, Torri V, Cavalli F, Johnson PW, Zucca E. A MALT lymphoma prognostic index. Blood. 2017 Sep 21:130(12):1409-1417. doi: 10.1182/blood-2017-03-771915. Epub 2017 Jul 18
[PubMed PMID: 28720586]
[11]
Wenzel C, Fiebiger W, Dieckmann K, Formanek M, Chott A, Raderer M. Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue of the head and neck area: high rate of disease recurrence following local therapy. Cancer. 2003 May 1:97(9):2236-41
[PubMed PMID: 12712477]
[12]
Sagaert X, de Paepe P, Libbrecht L, Vanhentenrijk V, Verhoef G, Thomas J, Wlodarska I, De Wolf-Peeters C. Forkhead box protein P1 expression in mucosa-associated lymphoid tissue lymphomas predicts poor prognosis and transformation to diffuse large B-cell lymphoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2006 Jun 1:24(16):2490-7
[PubMed PMID: 16636337]
[13]
Wündisch T, Thiede C, Morgner A, Dempfle A, Günther A, Liu H, Ye H, Du MQ, Kim TD, Bayerdörffer E, Stolte M, Neubauer A. Long-term follow-up of gastric MALT lymphoma after Helicobacter pylori eradication. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2005 Nov 1:23(31):8018-24
[PubMed PMID: 16204012]
[14]
Tomita N, Kodaira T, Tachibana H, Nakamura T, Mizoguchi N, Takada A. Favorable outcomes of radiotherapy for early-stage mucosa-associated lymphoid tissue lymphoma. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology. 2009 Feb:90(2):231-5. doi: 10.1016/j.radonc.2008.12.004. Epub 2009 Jan 8
[PubMed PMID: 19135751]
[15]
Tsang RW, Gospodarowicz MK, Pintilie M, Wells W, Hodgson DC, Sun A, Crump M, Patterson BJ. Localized mucosa-associated lymphoid tissue lymphoma treated with radiation therapy has excellent clinical outcome. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2003 Nov 15:21(22):4157-64
[PubMed PMID: 14615444]
Level 2 (mid-level) evidence
[16]
Fang P, Gunther JR, Pinnix CC, Dong W, Strati P, Nastoupil LJ, Steiner RE, Ahmed S, Damron EP, Fowler N, Nair R, Westin JR, Neelapu S, Ha CS, Dabaja BS. A Prospective Trial of Radiation Therapy Efficacy and Toxicity for Localized Mucosa-associated Lymphoid Tissue (MALT) Lymphoma. International journal of radiation oncology, biology, physics. 2021 Apr 1:109(5):1414-1420. doi: 10.1016/j.ijrobp.2020.11.070. Epub 2020 Dec 10
[PubMed PMID: 33309978]
[17]
Harada K, Murakami N, Kitaguchi M, Sekii S, Takahashi K, Yoshio K, Inaba K, Morota M, Ito Y, Sumi M, Suzuki S, Tobinai K, Uno T, Itami J. Localized ocular adnexal mucosa-associated lymphoid tissue lymphoma treated with radiation therapy: a long-term outcome in 86 patients with 104 treated eyes. International journal of radiation oncology, biology, physics. 2014 Mar 1:88(3):650-4. doi: 10.1016/j.ijrobp.2013.11.235. Epub
[PubMed PMID: 24521680]
[18]
Conconi A, Martinelli G, Thiéblemont C, Ferreri AJ, Devizzi L, Peccatori F, Ponzoni M, Pedrinis E, Dell'Oro S, Pruneri G, Filipazzi V, Dietrich PY, Gianni AM, Coiffier B, Cavalli F, Zucca E. Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of MALT type. Blood. 2003 Oct 15:102(8):2741-5
[PubMed PMID: 12842999]
[19]
Avilés A, Nambo MJ, Neri N, Talavera A, Cleto S. Mucosa-associated lymphoid tissue (MALT) lymphoma of the stomach: results of a controlled clinical trial. Medical oncology (Northwood, London, England). 2005:22(1):57-62
[PubMed PMID: 15750197]
Level 1 (high-level) evidence
[20]
Lee H, Yang B, Nam B, Jeong BH, Shin S, Zo JI, Shim YM, Kwon OJ, Lee KS, Kim H. Treatment outcomes in patients with extranodal marginal zone B-cell lymphoma of the lung. The Journal of thoracic and cardiovascular surgery. 2017 Jul:154(1):342-349. doi: 10.1016/j.jtcvs.2017.03.043. Epub 2017 Mar 21
[PubMed PMID: 28457544]
[21]
Saito Y, Watanabe N, Suzuki N, Saito N, Narimatsu H, Takami H, Kameyama K, Yoshioka K, Masaki C, Akaishi J, Hames KY, Matsumoto M, Fukushita M, Yoshihara A, Okamura R, Tomoda C, Suzuki A, Matsuzu K, Kitagawa W, Nagahama M, Noh JY, Sugino K, Ito K. Role of Surgery in Patients with Stage IE Primary Thyroid MALT Lymphoma Staged by a Modified Classification System: The Tokyo Classification. Cancers. 2023 Feb 24:15(5):. doi: 10.3390/cancers15051451. Epub 2023 Feb 24
[PubMed PMID: 36900242]
[22]
Goda JS, Gospodarowicz M, Pintilie M, Wells W, Hodgson DC, Sun A, Crump M, Tsang RW. Long-term outcome in localized extranodal mucosa-associated lymphoid tissue lymphomas treated with radiotherapy. Cancer. 2010 Aug 15:116(16):3815-24. doi: 10.1002/cncr.25226. Epub
[PubMed PMID: 20564130]
[23]
Smith CD, Gupta S, Sinn Chin Y, Thompson SR. Long term outcomes of gastric mucosa-associated lymphoid tissue lymphoma treated with radiotherapy: A multi-center retrospective cohort study. Hematological oncology. 2023 Feb:41(1):71-77. doi: 10.1002/hon.3078. Epub 2022 Oct 2
[PubMed PMID: 36150219]
Level 2 (mid-level) evidence
[24]
Wirth A, Gospodarowicz M, Aleman BM, Bressel M, Ng A, Chao M, Hoppe RT, Thieblemont C, Tsang R, Moser L, Specht L, Szpytma T, Lennard A, Seymour JF, Zucca E. Long-term outcome for gastric marginal zone lymphoma treated with radiotherapy: a retrospective, multi-centre, International Extranodal Lymphoma Study Group study. Annals of oncology : official journal of the European Society for Medical Oncology. 2013 May:24(5):1344-51. doi: 10.1093/annonc/mds623. Epub 2013 Jan 4
[PubMed PMID: 23293112]
Level 2 (mid-level) evidence
[25]
Lowry L, Smith P, Qian W, Falk S, Benstead K, Illidge T, Linch D, Robinson M, Jack A, Hoskin P. Reduced dose radiotherapy for local control in non-Hodgkin lymphoma: a randomised phase III trial. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology. 2011 Jul:100(1):86-92. doi: 10.1016/j.radonc.2011.05.013. Epub 2011 Jun 12
[PubMed PMID: 21664710]
Level 2 (mid-level) evidence
[26]
Hoskin PJ, Kirkwood AA, Popova B, Smith P, Robinson M, Gallop-Evans E, Coltart S, Illidge T, Madhavan K, Brammer C, Diez P, Jack A, Syndikus I. 4 Gy versus 24 Gy radiotherapy for patients with indolent lymphoma (FORT): a randomised phase 3 non-inferiority trial. The Lancet. Oncology. 2014 Apr:15(4):457-63. doi: 10.1016/S1470-2045(14)70036-1. Epub 2014 Feb 24
[PubMed PMID: 24572077]
Level 1 (high-level) evidence
[27]
Yahalom J, Illidge T, Specht L, Hoppe RT, Li YX, Tsang R, Wirth A, International Lymphoma Radiation Oncology Group. Modern radiation therapy for extranodal lymphomas: field and dose guidelines from the International Lymphoma Radiation Oncology Group. International journal of radiation oncology, biology, physics. 2015 May 1:92(1):11-31. doi: 10.1016/j.ijrobp.2015.01.009. Epub
[PubMed PMID: 25863750]
[28]
Venerito M, Krieger T, Ecker T, Leandro G, Malfertheiner P. Meta-analysis of bismuth quadruple therapy versus clarithromycin triple therapy for empiric primary treatment of Helicobacter pylori infection. Digestion. 2013:88(1):33-45. doi: 10.1159/000350719. Epub 2013 Jul 19
[PubMed PMID: 23880479]
Level 1 (high-level) evidence
[29]
Chen LT, Lin JT, Tai JJ, Chen GH, Yeh HZ, Yang SS, Wang HP, Kuo SH, Sheu BS, Jan CM, Wang WM, Wang TE, Wu CW, Chen CL, Su IJ, Whang-Peng J, Cheng AL. Long-term results of anti-Helicobacter pylori therapy in early-stage gastric high-grade transformed MALT lymphoma. Journal of the National Cancer Institute. 2005 Sep 21:97(18):1345-53
[PubMed PMID: 16174856]
[30]
Steinbach G, Ford R, Glober G, Sample D, Hagemeister FB, Lynch PM, McLaughlin PW, Rodriguez MA, Romaguera JE, Sarris AH, Younes A, Luthra R, Manning JT, Johnson CM, Lahoti S, Shen Y, Lee JE, Winn RJ, Genta RM, Graham DY, Cabanillas FF. Antibiotic treatment of gastric lymphoma of mucosa-associated lymphoid tissue. An uncontrolled trial. Annals of internal medicine. 1999 Jul 20:131(2):88-95
[PubMed PMID: 10419446]
[31]
Martinelli G, Laszlo D, Ferreri AJ, Pruneri G, Ponzoni M, Conconi A, Crosta C, Pedrinis E, Bertoni F, Calabrese L, Zucca E. Clinical activity of rituximab in gastric marginal zone non-Hodgkin's lymphoma resistant to or not eligible for anti-Helicobacter pylori therapy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2005 Mar 20:23(9):1979-83
[PubMed PMID: 15668468]
[32]
Ferreri AJ, Govi S, Pasini E, Mappa S, Bertoni F, Zaja F, Montalbán C, Stelitano C, Cabrera ME, Giordano Resti A, Politi LS, Doglioni C, Cavalli F, Zucca E, Ponzoni M, Dolcetti R. Chlamydophila psittaci eradication with doxycycline as first-line targeted therapy for ocular adnexae lymphoma: final results of an international phase II trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2012 Aug 20:30(24):2988-94. doi: 10.1200/JCO.2011.41.4466. Epub 2012 Jul 16
[PubMed PMID: 22802315]
[33]
Han JJ, Kim TM, Jeon YK, Kim MK, Khwarg SI, Kim CW, Kim IH, Heo DS. Long-term outcomes of first-line treatment with doxycycline in patients with previously untreated ocular adnexal marginal zone B cell lymphoma. Annals of hematology. 2015 Apr:94(4):575-81. doi: 10.1007/s00277-014-2240-8. Epub 2014 Oct 24
[PubMed PMID: 25338969]